Tibotec BVBA clinical trials

Acquired by Johnson & Johnson, Apr 2002 · source ↗

The registry lists 18 studies whose lead sponsor is Tibotec BVBA. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 25, 2014.

Studies

Recruiting first, then most recently updated. Showing 18 of 18. All Johnson & Johnson studies →

• An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C ParticipantsCompletedNCT00528528Phase 2

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)CompletedNCT00910806Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard TreatmentCompletedNCT00703118Phase 3

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT00580801Phase 2

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C InfectionCompletedNCT00561015Phase 2

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy ParticipantsCompletedNCT00946842Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• A Study of TMC207 in Patients With Moderately Impaired Hepatic FunctionCompletedNCT01012284Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-StateCompletedNCT00933283Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed ConditionsCompletedNCT01291563Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + RibavirinTerminatedNCT01391117Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and RaltegravirCompletedNCT01253551Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy VolunteerCompletedNCT00828529Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive TuberculosisCompletedNCT00523926Phase 2

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.CompletedNCT00903773Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy VolunteerCompletedNCT00828789Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and EscitalopramCompletedNCT00933894Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.CompletedNCT00775125Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson

• VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy VolunteersCompletedNCT00973388Phase 1

  Sponsor listed in the registry: Tibotec BVBA · First submitted after Tibotec BVBA became part of Johnson & Johnson